Pre Clinical Therapeutics Development Program
Overview
The Pre-Clinical Therapeutics Development Program supports research studies focused on the development of novel assays or HIV-gene reporter systems in appropriate cells/lines which would ultimately be useful in screening therapeutic compounds and treatment strategies that protect against HIV or HAART-related neurotoxicity. The development or validation of animal models (rodent or SIV in particular) useful for drug screening is also encouraged.
The program also supports basic and pilot clinical therapeutics research directed at understanding the long-term biological consequences of taking anti-retroviral medications in the presence of other medications (particularly psychiatric medications) used to treat comorbid conditions.
Areas of Emphasis
- Develop novel assays or HIV-gene reporter systems in appropriate cells/lines which would ultimately be useful in screening therapeutic compounds and treatment strategies that protect against HIV or HAART-related neurotoxicity.
- Develop or validate animal models (rodent or SIV in particular) useful for drug screening.
- Basic and pilot clinical therapeutics research directed at understanding the long-term biological consequences of taking anti-retroviral medications in the presence of other medications (particularly psychiatric medications) used to treat comorbid conditions.
Contact
Jeymohan Joseph, Ph.D.
Program Officer
6001 Executive Boulevard, Room 6202, MSC 9619
301-443-3012, jjeymoha@mail.gov
